share_log

Helius Medical Technologies' PoNS Now Available On The VA Federal Supply Schedule And General Services Administration Advantage Contracts; PoNS System, Item # S1-001-02, Priced At $23,843.72 And The PoNS Mouthpiece, Item # M1-001, Priced At $7,344.97

Helius Medical Technologies' PoNS Now Available On The VA Federal Supply Schedule And General Services Administration Advantage Contracts; PoNS System, Item # S1-001-02, Priced At $23,843.72 And The PoNS Mouthpiece, Item # M1-001, Priced At $7,344.97

Helius Medical Technologies的PON現已在弗吉尼亞州聯邦供應計劃和總務管理局的優勢合同中提供;PonS系統,商品編號 S1-001-02,定價爲23,843.72美元;PonS喉舌,商品編號 M1-001,定價爲7,344.97美元
Benzinga ·  05/20 21:02

-- Approval provides U.S. veterans and other U.S. government agency employees who suffer gait and balance impairment due to multiple sclerosis (MS) access to the only portable neurostimulation therapy with the potential to generate neuroplasticity --

— 批准爲因多發性硬化症(MS)而遭受步態和平衡障礙的美國退伍軍人和其他美國政府機構僱員提供唯一有可能產生神經可塑性的便攜式神經刺激療法——

NEWTOWN, Pa., May 20, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced the Company's Portable Neuromodulation Stimulator (PoNS) device has been approved for inclusion on Lovell Government Services' ("Lovell") Veterans Affairs (VA) Federal Supply Schedule (FSS) and General Services Administration (GSA) Advantage contracts.

賓夕法尼亞州紐敦,2024年5月20日(GLOBE NEWSWIRE)——專注於爲平衡和步態缺陷提供新型治療性神經調節方法的神經科技公司Helius Medical Technologies, Inc.(納斯達克股票代碼:HSDT)(“Helius” 或 “公司”)今天宣佈,該公司的便攜式神經調節刺激器(PonS)設備已獲准納入洛弗爾政府服務公司(“洛弗爾”)退伍軍人事務部(VA)聯邦供應計劃(FSS)和總務管理局(GSA)優勢合同。

The contract award number #V797D-50450 enables the VA and other Federal entities to purchase PoNS at pre-approved pricing via the VA's FSS Medical Equipment and Surgical (Med/Surg) Contract at VA National Acquisition Center MedSurg Catalog and via the GSA Advantage online catalog at GSA Advantage. The PoNS system, Item # S1-001-02, is priced at $23,843.72 and the PoNS mouthpiece, Item # M1-001 is priced at $7,344.97. PoNS is indicated in the U.S. for use as a short-term treatment of gait deficit in adults with mild-to-moderate symptoms from MS when used in conjunction with physical therapy.

合同授標編號 #V797D -50450 使弗吉尼亞州和其他聯邦實體能夠通過弗吉尼亞州國家採購中心MedSurg目錄中的弗吉尼亞州FSS醫療設備和外科(Med/Surg)合同以及GSA Advantage的GSA Advantage在線目錄以預先批准的價格購買PON。PonS 系統的商品編號爲 S1-001-02,售價爲 23,843.72 美元,而 PonS 的喉舌 M1-001 的售價爲 7,344.97 美元。在美國,當與物理療法結合使用時,PonS可用作短期步態缺陷治療因多發性硬化症而出現輕度至中度症狀的成年人的步態缺陷。

The VA estimates that between 55,000 and 70,000 veterans in the U.S. live with MS.

弗吉尼亞州估計,美國有55,000至7萬名退伍軍人患有多發性硬化症

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論